NCT06615752 2026-04-15
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
Phase 1/2 Recruiting
Clinical Trials
171 trialsNCT06931340 2026-04-07
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06282588 2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT03574571 2026-02-27
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT03246347 2026-01-23
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03258320 2026-01-12
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine
Phase 2/3 Recruiting
NCT07333066 2026-01-12
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3 Not yet recruiting
NCT07316686 2026-01-05
Lutécio
Instituto do Cancer do Estado de São Paulo
Phase 1 Not yet recruiting
NCT07268794 2025-12-08
CONVERT-HB1
Fudan University
Phase 2 Not yet recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06060587 2025-10-22
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Phase 2 Withdrawn
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT07172685 2025-09-15
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
Phase NA Recruiting
NCT03951831 2025-04-25
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Columbia University
Phase 2 Active not recruiting
NCT06864533 2025-04-24
PKUFH-GS5
Peking University First Hospital
Phase NA Recruiting
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT06446401 2025-03-04
Lead4Care
Uppsala University
Recruiting
NCT05676203 2025-02-17
ARASAFE
Jena University Hospital
Phase 3 Active not recruiting
NCT04812366 2024-12-16
GUNS
University of British Columbia
Phase 2 Recruiting
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT01957436 2024-11-12
PEACE1
UNICANCER
Phase 3 Active not recruiting
NCT05156905 2024-10-09
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
University of California, San Diego
Phase 1 Terminated
NCT03230734 2024-09-27
RAPSON
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Active not recruiting
NCT01446731 2024-07-03
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Herlev Hospital
Phase 2 Completed
NCT06473259 2024-06-25
ECHOS
Santa Chiara Hospital
Recruiting
NCT03066154 2024-06-03
DOP
The Netherlands Cancer Institute
Phase 1 Terminated
NCT02453009 2024-05-30
CHEIRON
Santa Chiara Hospital
Phase 2 Completed
NCT06430411 2024-05-28
OLIGOMET
Medical University of Vienna
Not yet recruiting
NCT03358563 2024-05-03
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Completed
NCT03700099 2024-04-15
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT03311555 2024-03-19
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Duke University
Phase 2 Completed
NCT05627752 2024-02-28
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
Zhongnan Hospital
Phase 2/3 Unknown
NCT00099086 2024-01-31
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00176631 2023-12-22
Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT03837353 2023-12-18
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
NYU Langone Health
Phase 1/2 Terminated
NCT00482807 2023-11-24
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
Phase 1 Completed
NCT00587431 2023-11-07
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00786682 2023-08-14
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT05983783 2023-08-09
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT02516670 2023-06-07
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00430183 2023-02-09
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT00055731 2023-01-18
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
Phase 3 Completed
NCT02598895 2022-11-17
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
Phase 2 Completed